242 related articles for article (PubMed ID: 35013918)
41. Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form.
Lin FJ; Pickard AS; Krishnan JA; Joo MJ; Au DH; Carson SS; Gillespie S; Henderson AG; Lindenauer PK; McBurnie MA; Mularski RA; Naureckas ET; Vollmer WM; Lee TA;
BMC Med Res Methodol; 2014 Jun; 14():78. PubMed ID: 24934150
[TBL] [Abstract][Full Text] [Related]
42. Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing.
Zhu J; Yan XX; Liu CC; Wang H; Wang L; Cao SM; Liao XZ; Xi YF; Ji Y; Lei L; Xiao HF; Guan HJ; Wei WQ; Dai M; Chen W; Shi JF
Qual Life Res; 2021 Mar; 30(3):841-854. PubMed ID: 32930993
[TBL] [Abstract][Full Text] [Related]
43. [Development of the German version of EQ-5D-Y-5L to measure health-related quality of life in children and adolescents: Identification of response labels and pilot testing].
Kreimeier S; Greiner W
Z Evid Fortbild Qual Gesundhwes; 2019 Aug; 144-145():24-34. PubMed ID: 31378708
[TBL] [Abstract][Full Text] [Related]
44. Comparing the EQ-5D-5L and stroke impact scale 2.0 in stroke patients: an analysis of measurement properties.
Schmidt J; Düvel JA; Elkenkamp S; Greiner W
Health Qual Life Outcomes; 2024 Jun; 22(1):45. PubMed ID: 38835023
[TBL] [Abstract][Full Text] [Related]
45. The construct validity and responsiveness of the EQ-5D-5L, AQL-5D and a bespoke TTO in acute asthmatics.
Crossman-Barnes CJ; Sach T; Wilson A; Barton G
Qual Life Res; 2020 Mar; 29(3):619-627. PubMed ID: 31676971
[TBL] [Abstract][Full Text] [Related]
46. Validation of Brunei's Malay EQ-5D Questionnaire in Patients with Type 2 Diabetes.
Koh D; Abdullah AM; Wang P; Lin N; Luo N
PLoS One; 2016; 11(11):e0165555. PubMed ID: 27835652
[TBL] [Abstract][Full Text] [Related]
47. Quality of life of the Indonesian general population: Test-retest reliability and population norms of the EQ-5D-5L and WHOQOL-BREF.
Purba FD; Hunfeld JAM; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJV
PLoS One; 2018; 13(5):e0197098. PubMed ID: 29750806
[TBL] [Abstract][Full Text] [Related]
48. EQ-5D-Y-3L and EQ-5D-Y-5L proxy report: psychometric performance and agreement with self-report.
Fitriana TS; Purba FD; Stolk E; Busschbach JJV
Health Qual Life Outcomes; 2022 Jun; 20(1):88. PubMed ID: 35659313
[TBL] [Abstract][Full Text] [Related]
49. Linguistic and Psychometric Validation of the Cognition Bolt-On Version of the Japanese EQ-5D-5L for the Elderly.
Igarashi A; Sakata Y; Azuma-Kasai M; Kamiyama H; Kawaguchi M; Tomita K; Ishii M; Ikeda M
J Alzheimers Dis; 2023; 91(4):1447-1458. PubMed ID: 36641680
[TBL] [Abstract][Full Text] [Related]
50. Reliability of the quality of life-aged care consumers (QOL-ACC) and EQ-5D-5L among older people using aged care services at home.
Khadka J; Milte R; Hutchinson C; Cleland J; Ratcliffe J
Health Qual Life Outcomes; 2024 May; 22(1):40. PubMed ID: 38816717
[TBL] [Abstract][Full Text] [Related]
51. Health-Related Quality of Life in Romanian Patients with Dystonia: An Exploratory Study.
Băjenaru OL; Nuță CR; Băjenaru L; Balog A; Constantinescu A; Andronic O; Popescu BO
J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38929932
[No Abstract] [Full Text] [Related]
52. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea.
Kim SH; Kim HJ; Lee SI; Jo MW
Qual Life Res; 2012 Aug; 21(6):1065-73. PubMed ID: 21947656
[TBL] [Abstract][Full Text] [Related]
53. Translation, validity and reliability of the British Sign Language (BSL) version of the EQ-5D-5L.
Rogers KD; Pilling M; Davies L; Belk R; Nassimi-Green C; Young A
Qual Life Res; 2016 Jul; 25(7):1825-34. PubMed ID: 26887955
[TBL] [Abstract][Full Text] [Related]
54. Validity of the EQ-5D-5L questionnaire among the general population of Poland.
Młyńczak K; Golicki D
Qual Life Res; 2021 Mar; 30(3):817-829. PubMed ID: 33099710
[TBL] [Abstract][Full Text] [Related]
55. Psychometric properties comparison between EQ-5D-5L and EQ-5D-3L in the general Thai population.
Kangwanrattanakul K; Parmontree P
Qual Life Res; 2020 Dec; 29(12):3407-3417. PubMed ID: 32780315
[TBL] [Abstract][Full Text] [Related]
56. Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.
Rencz F; Lakatos PL; Gulácsi L; Brodszky V; Kürti Z; Lovas S; Banai J; Herszényi L; Cserni T; Molnár T; Péntek M; Palatka K
Qual Life Res; 2019 Jan; 28(1):141-152. PubMed ID: 30225788
[TBL] [Abstract][Full Text] [Related]
57. Examining the psychometric properties of a split version of the EQ-5D-5L anxiety/depression dimension in patients with anxiety and/or depression.
Belay YB; Mihalopoulos C; Lee YY; Mulhern B; Engel L
Qual Life Res; 2023 Jul; 32(7):2025-2036. PubMed ID: 36809437
[TBL] [Abstract][Full Text] [Related]
58. Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis.
Yfantopoulos J; Chantzaras A; Kontodimas S
Arch Dermatol Res; 2017 Jul; 309(5):357-370. PubMed ID: 28528371
[TBL] [Abstract][Full Text] [Related]
59. A head-to-head comparison of the EQ-5D-5L and 15D descriptive systems and index values in a general population sample.
Nikl A; Janssen MF; Brodszky V; Rencz F
Health Qual Life Outcomes; 2023 Feb; 21(1):17. PubMed ID: 36803866
[TBL] [Abstract][Full Text] [Related]
60. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.
Poór AK; Rencz F; Brodszky V; Gulácsi L; Beretzky Z; Hidvégi B; Holló P; Kárpáti S; Péntek M
Qual Life Res; 2017 Dec; 26(12):3409-3419. PubMed ID: 28875430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
